Generic filters

LCTX – Lineage Cell Therapeutics Inc


The company is Shariah Compliant, according to AAOIFI methodology.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cell therapies to address unmet medical needs. It designs, develops, and manufactures specialized human cells with anatomical and physiological functions which are similar or identical to cells found naturally in the human body. It has five allogeneic product candidates: OpRegen, OPC1, VAC2, ANP1, and PNC1. OpRegen is a retinal pigment epithelium (RPE) cell replacement therapy in a Phase IIa development for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD). OPC1 is an oligodendrocyte progenitor cell therapy in a Phase I/IIa development for the treatment of acute spinal cord injuries (SCI); VAC is a dendritic cell therapy produced from Lineages VAC technology platform for immuno-oncology and infectious disease, in Phase I clinical development for the treatment of non-small cell lung cancer.


Debt ÷ Market cap (MC)0.05
Non-Compliant Assets ÷ MC19.53

Found the Stock You’re Looking For? Open an Account Today!

Opening an account has never been easier! Please fill out the form here and an advisor will be in touch to walk you through the process!

Still have some further questions?